Abstract: The present disclosure provides IL12 and IL23 muteins as partial agonists comprising modified human p40 molecules that associate with human p35 (hP35) and human P19 (hP19) to form modified hIL-12 and IL23 partial agonists wherein the individual components of IL12 and IL23 muteins are linked to engineered Fc domains.

Abstract: Provided herein am IL2R binding proteins that bind to IL2R? and IL2R? and comprise an anti-IL2R? VHH antibody and an anti-IL2R? VHH antibody.

Abstract: The invention provides anti-TIGIT (T-cell immunoreceptor with Ig and ITIM domains) antibodies and methods of using the same.

Abstract: The present disclosure provides methods of identifying a disease-specific immunogenic peptide through a series of selection steps. Immunogenic epitopes identified by methods of the present disclosure are applicable for use in peptide-based immunotherapy, preferably cancer therapy. Furthermore, the methods of the present disclosure may be performed in a high-throughput manner and serve as a means of personalized vaccine development and therapy. Also provided are compositions of immunogenic peptides as well as methods of treatment comprising said compositions.

Abstract: Provided herein are IL27R binding proteins that bind to IL27R? and gp130 and comprise an anti-IL27R? VHH antibody and an anti-gp130 VHH antibody.

Abstract: Provided herein are IL10R?/IL2R? binding proteins that bind to IL10R? and IL2R? and comprise an anti-IL10R? VHH antibody and an anti-IL2R? VHH antibody.

Abstract: Provided herein are IL27R binding proteins that bind to IL27R? and gp130 and comprise an anti-IL27R? VHH antibody and an anti-gp130 VHH antibody.

Abstract: The present disclosure provides methods of identifying a disease-specific immunogenic peptide through a series of selection steps. Immunogenic epitopes identified by methods of the present disclosure are applicable for use in peptide-based immunotherapy, preferably cancer therapy. Furthermore, the methods of the present disclosure may be performed in a high-throughput manner and serve as a means of personalized vaccine development and therapy. Also provided are compositions of immunogenic peptides as well as methods of treatment comprising said compositions.

Abstract: The present disclosure provides IL12 and IL23 muteins as partial agonists comprising modified human p40 molecules that associate with human p35 (hP35) and human P19 (hP19) to form modified hIL-12 and IL23 partial agonists wherein the individual components of IL12 and IL23 muteins are linked to engineered Fc domains.

Abstract: The present disclosure provides IL12 and IL23 muteins as partial agonists comprising modified human p40 molecules that associate with human p35 (hP35) and human P19 (hP19) to form modified hIL-12 and IL23 partial agonists wherein the individual components of IL12 and IL23 muteins are linked to engineered Fc domains.

Abstract: Provided herein are IL27R binding proteins that bind to IL27R? and gp130 and comprise an anti-IL27R? VHH antibody and an anti-gp130 VHH antibody.

Abstract: The present disclosure relates to biologically active molecules comprising a single comain antibody (sdAb) that specifically binds to the extracellular domain of human IL12RM, compositions comprising such antibodies, and methods of use thereof.

Abstract: The present disclosure provides IL12 and IL23 muteins as partial agonists comprising modified human p40 molecules that associate with human p35 (hP35) and human P19 (hP19) to form modified hIL-12 and IL23 partial agonists wherein the individual components of IL12 and IL23 muteins are linked to engineered Fc domains.

Abstract: The invention provides anti-TIGIT (T-cell immunoreceptor with Ig and ITIM domains) antibodies and methods of using the same.

Abstract: Provided herein are IL27R binding proteins that bind to IL27R? and gp130 and comprise an anti-IL27R? VHH antibody and an anti-gp130 VHH antibody.

Abstract: Provided herein are IL27R binding proteins that bind to IL27R? and gp130 and comprise an anti-IL27R? VHH antibody and an anti-gp130 VHH antibody.

Abstract: The invention provides anti-TIGIT (T-cell immunoreceptor with Ig and ITIM domains) antibodies and methods of using the same.

Abstract: The invention provides anti-TIGIT (T-cell immunoreceptor with Ig and ITIM domains) antibodies and methods of using the same.

Abstract: The invention provides anti-TIGIT (T-cell immunoreceptor with Ig and ITIM domains) antibodies and methods of using the same.

Abstract: The invention provides anti-TIGIT (T-cell immunoreceptor with Ig and ITIM domains) antibodies and methods of using the same.